# US 2018/0021282 A1 · Ophthalmic compositions and methods for treating eyes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021282 A1
- Document ID: US20180021282A1
- Status: Published application
- Kind: A1
- Application number: 15/585,888
- Filed: 2017-05-03
- Published: 2018-01-25
- Earliest claimed: 2004-11-16
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Joseph G. Vehige; Peter A. Simmons; Joan-En Chang-Lin
- Web page: https://patentgrep.com/patent/US20180021282A1

## CPC

- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/717: Celluloses
- A61K 31/728: Hyaluronic acid
- A61K 38/1732: {Lectins}
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.

## Claims

### Claim 1

A method of treating one or more ocular surface complications in a patient subject to a surgical procedure in which at least one eye of the patient is exposed to laser energy, wherein the treatment comprises administering to the ocular surface an aqueous solution comprising ophthalmically acceptable amounts of:
erythritol, and its isomers thereof;
carnitine, its isomers and suitable salts thereof;
glycerin; and
an ionically charged polymeric material selected from the group consisting of carboxymethyl cellulose and mixtures of carboxymethyl cellulose compounds.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ocular surface complication comprises keratitis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ocular surface complication comprises chemical damage to the ocular surface.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ocular surface complication comprises keratoconjunctivitis sicca.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ocular surface complication comprises neurotrophic hyperesthesia.

### Claim 6 (depends on 1)

The method of claim 1, wherein the surgical procedure comprises Laser-Assisted In Situ Keratomileusis (LASIK).

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition further comprises stabilized chlorine dioxide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is administered after the surgical procedure.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is administered during the surgical procedure.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is administered prior to the surgical procedure.

### Claim 11

A method of increasing comfort in a patient wearing contact lenses, the method comprising applying to at least one eye of the patient a composition comprising therapeutically effective amounts of erythritol, carnitine, glycerin, carboxymethyl cellulose, and water.

### Claim 12 (depends on 11)

The method of claim 11, wherein the composition further comprises stabilized chlorine dioxide.

### Claim 13 (depends on 11)

The method of claim 11, wherein the patient comfort is increased by reducing the incidence of one or more of ocular dryness and discomfort during contact lens wear after administration of the composition.